1 min de lecture
[Press Release] Accelarated Scientific Advise from European Medicines Adgency EMA for XAV19 Market Authorisation
-
-
Auteurcontact@xenothera.com
-
Publié18 juillet 2021
Articles récents
[Press Alert] Omicron Variant : positive results for XENOTHERA's XAV-19 antibody
# Download our press information (english version) # Télécharger notre communiqué de...
More[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.
January 2022. # Download our press information (english version) # Télécharger notre...
More[ Press Information ]The French biotech XENOTHERA awarded Start-Up of the Year for the Western region.
# Download our press information (english version) # Télécharger notre information presse...
More